---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-114414"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:38:46.731766+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iovance Q3 net loss $99.6M ($0.63/sh); BLA submission for lifileucel on track to complete in Q4 2022

## Summary
- Cash, equivalents, investments & restricted cash $366.6M at Sep 30, 2022, down from $602.1M at Dec 31, 2021; runway into 2024.
- Net loss $99.6M vs $86.1M YoY; R&D expense $72.5M (+$7.1M), G&A $27.9M (+$7.0M).
- Rolling BLA for lifileucel in advanced melanoma started August 2022, expected to complete in Q4 2022.
- Phase 3 trial of lifileucel + pembrolizumab in frontline advanced melanoma on track to begin late 2022.
- iCTC facility annual capacity for 2,000+ patients; new cGMP manufacturing suites for commercial supply.

## SEC filing metadata
- accession: 0001104659-22-114414
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465922114414/0001104659-22-114414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465922114414/tm2229606d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-114414
- JSON: https://secwatch.observer/filing/0001104659-22-114414.json
- Plain text: https://secwatch.observer/filing/0001104659-22-114414.txt

## Key facts
- Earnings Releases
  IOVANCE BIOTHERAPEUTICS, INC. reported the quarter ended September 30, 2022 results: net income $99.6 million, or $0.63 per share, EPS $0.63 per share.
  - Period: the quarter ended September 30, 2022
  - Net income: $99.6 million, or $0.63 per share
  - EPS: $0.63 per share
  - Result: reported results
  source text: Net loss for the third quarter ended September 30, 2022, was $99.6 million, or $0.63 per share, compared to a net loss of $86.1 million, or $0.55 per share, for the third quarter ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465922114414/0001104659-22-114414-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.